FindTrial
Sign In

Efficacy of Tranexamic Acid combined with Carbazochrome Sodium Sulfonate on blood loss in primary total hip arthroplasty using a direct anterior approach: a prospective randomized controlled trial

Blood loss management and fast rehabilitation for patients undergoing total hip arthroplaty

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800015834
Enrollment
Unknown
Registered
2018-04-24
Start date
2018-05-03
Completion date
Unknown
Last updated
2019-01-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

osteoarthritis or Osteonecrosis of femoral head

Interventions

Group 1:Tranexamic acid ( intravenous injection) + Carbazochrome Sodium Sulfonate (Infiltration of the surrounding tissue of the capsule + intravenous injection)
Group 2:Tranexamic acid ( intravenous injection) + Carbazochrome Sodium Sulfonate (Infiltration of the surrounding tissue of the capsule)
Group 3:Tranexamic acid ( intravenous injection) + Carbazochrome Sodium Sulfonate ( intravenous injection)
Group 4:Tranexamic acid (intravenous injection)

Sponsors

Department of Orthopedics, West China Hospital, Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1. patients with osteoarthritis or osteonecrosis of the femoral head (Ficat III?IV) and have to undergo THA; 2. BMI: 20-35 kg/m2; 3. American Society of Anesthesiologists degree before operation: I~III grade; 4. Aged 18 years and above.

Exclusion criteria

Exclusion criteria: 1. The patients with anaphylactic acid, sodium carboxylic acid, anaesthesia drug allergy; 2. have a rigid hip joint, severe femoral deformity; 3. The posterior wall of the acetabulum was removed, and there was a history of surgery in the posterior hip; 4. The osteoarthritis (Crowe type 3 or 4) of DDH and femoral head necrosis; 5. The history of thromboembolic disease (DVT), pulmonary embolism (PE), coagulopathy, recent arterial thromboembolic events (such as myocardial infarction or stroke), hypercoagulability, hemophilia; 6. Severe cardiovascular and respiratory diseases; Kidney and liver failure, kidney transplantation history; 7. Persons who refuse to participate in or refuse to accept blood products; 8. The patient had a history of bilateral hip arthroplasty, using anticoagulants or contraceptives five days before surgery.

Design outcomes

Primary

MeasureTime frame
total blood loss;haemoglobin (HB);haematocrit;reduction in haemoglobin concentration;D-dimer;—

Secondary

MeasureTime frame
intra-operative blood loss;transfusion rates;Thromboelastographic;inflammatory cytokines;range of motion of the hip;Length of postoperative hospital stay;—

Countries

China

Contacts

Public ContactKang Pengde

Department of Orthopedics, West China Hospital, Sichuan University

kangpd@163.com+86 18980601953

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026